A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...

Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.1 In contrast, in previous studies ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 ...

Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP ...

ImmunoPrecise Antibodies (IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...